Abstract: A battery system includes a nickel-metal hydride battery and an ECU that controls charging and discharging of the nickel-metal hydride battery. The ECU calculates a discharge electricity amount showing an integrated value of a current discharged from the nickel-metal hydride battery, and further calculates ?SOC of the nickel-metal hydride battery in a prescribed time period. The ECU calculates a charge reserve capacity of the nickel-metal hydride battery based on a temperature of the nickel-metal hydride battery, the discharge electricity amount, and the ?SOC.

Abstract: An oxoisoquinoline compound of the following formula: or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the oxoisoquinoline compound or salt; and a method for treating B-cell lymphoma comprising administering the oxoisoquinoline compound or salt to a patient.

Abstract: Herein disclosed are compounds, compositions, kits, and methods of treating cancers using 7-azaindolyl furanone/thiophene derivatives. These derivatives inhibit serine-threonine kinase Cdc7, a recognized anticancer target affecting DNA replication. Further, the compounds disclosed herein possess potent inhibitory activity in the presence of adenosine triphosphate (ATP), demonstrate significant kinase selectivity, and offer advantages over known Cdc7 inhibitors with prolonged half-life and inhibitory effects.

Abstract: The present invention provides with an oxoisoquinoline derivative represented by the formula (I) (in the formula, Q and R1 are as defined in the description) or a pharmaceutically acceptable salt thereof, which is useful as a Bruton's kinase inhibitor for treating cancer, B-cell lymphoma, chronic lymphocytic leukemia and the like.

Abstract: The purpose of the present invention is to provide a novel triazine derivative of the formula (I): wherein R1 represents a substituted or unsubstituted lower alkyl group, R2 represents a hydrogen atom or a substituted or unsubstituted lower alkyl group, A represents a nitrogen atom or C—R3, R3 represents a hydrogen atom, a cyano group, a substituted or unsubstituted acyl group, a substituted or unsubstituted sulfonyl group, or a substituted or unsubstituted carbamoyl group, and R4 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group, or a pharmaceutically acceptable salt thereof.

Abstract: To provide a novel 2,6-diaminopyrimidine derivative by the following formula (I): A 2,6-diaminopyrimidine derivative is represented by the formula (I): wherein R1 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group, Ar represents a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group, Z1 and Z2 represent carbon atoms, or either 1 or 2 of the Z1 and Z2 represent nitrogen atoms, Q is selected from a structure (a) or (b) described below: R2 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group, R3 represents a hydrogen atom or a halogen atom, Y represents a nitrogen atom or a carbon atom, and the bond drawn with a dotted line parallel to a solid line on structure (a) represents either double bond or single bond.

Abstract: The purpose of the present invention is to provide a novel triazine derivative of the formula (I): wherein R1 represents a substituted or unsubstituted lower alkyl group, R2 represents a hydrogen atom or a substituted or unsubstituted lower alkyl group, A represents a nitrogen atom or C—R3, R3 represents a hydrogen atom, a cyano group, a substituted or unsubstituted acyl group, a substituted or unsubstituted sulfonyl group, or a substituted or unsubstituted carbamoyl group, and R4 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group, or a pharmaceutically acceptable salt thereof.

Abstract: An exhaust treatment unit is used to treat an exhaust gas from an engine of the work vehicle. The exhaust treatment unit includes a first exhaust treatment device, a second exhaust treatment device and a first bracket. The first exhaust treatment device and the second exhaust treatment device are attached to the first bracket. The first bracket includes a brim part and a main body part. The main body part has a convex shape downwardly bulged from the brim part. The main body part includes a first support portion and a second support portion. The first support portion directly supports the first exhaust treatment device. The second support portion directly supports the second exhaust treatment device.

Abstract: An exhaust treatment unit is used to treat an exhaust gas from an engine of the work vehicle. The exhaust treatment unit includes a first exhaust treatment device, a second exhaust treatment device and a first bracket. The first exhaust treatment device and the second exhaust treatment device are attached to the first bracket. The first bracket includes a brim part and a main body part. The main body part has a convex shape downwardly bulged from the brim part. The main body part includes a first support portion and a second support portion. The first support portion directly supports the first exhaust treatment device. The second support portion directly supports the second exhaust treatment device.

Abstract: To provide a novel triazine derivative represented by the following formula (I): A triazine derivative represented by the following formula (I): wherein R1 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, a substituted or unsubstituted heterocyclic fused ring, or a substituted or unsubstituted alkynyl group, R2 represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group, R3 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, or a substituted or unsubstituted heterocyclic fused ring, R4 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, or a halogen atom, and R5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, or R1 and R5 may be combined to form a saturated or unsaturate

Abstract: To provide a novel furanone derivative, and a medicine including the same.

Abstract: To provide a novel furanone derivative, and a medicine including the same.

Abstract: An object of the present invention is to provide thiazolidinone derivatives. More specifically, an object of the present invention is to provide novel compounds having a CDC7 inhibitory action. The present invention provides thiazolidinone derivatives represented by the formula (I) The compounds of the present invention inhibit the CDC7 protein kinase activity, and suppress cell proliferation.

Abstract: An object of the present invention is to provide thiazolidinone derivatives. More specifically, an object of the present invention is to provide novel compounds having a CDC7 inhibitory action. The present invention provides thiazolidinone derivatives represented by the formula (I) The compounds of the present invention inhibit the CDC7 protein kinase activity, and suppress cell proliferation.

Abstract: In an indoor type skiing ground having a ski slope formed by sprinkling artificial snow to a predetermined thickness on a slope inside a building, a predetermined height range from the surface of the artificial snow is defined as a low temperature region, while an ordinary temperature region is defined above the low temperature region, and cold air ports for blowing cold air into the building are formed in a side wall of the building so as to be located in the low temperature region, while air outlets are formed so as to be located above the cold air ports.

Abstract: To provide a novel furanone derivative, and a medicine including the same.

Abstract: To provide a novel furanone derivative, and a medicine including the same.